These Analysts Boost Their Forecasts On Abbott Laboratories After Better-Than-Expected Earnings

Benzinga

17 Apr

Abbott Laboratories (NYSE:ABT) reported better-than-expected first-quarter adjusted EPS results on Wednesday.

Abbott Laboratories reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the consensus of $10.40 billion. The U.S. MedTech giant reported adjusted EPS of $1.09, beating the consensus of $1.07 and the management guidance of $1.05-$1.09.

"Once again, Abbott's diversified business model delivered top-tier sales and EPS growth," said Robert Ford, chairman and CEO of Abbott. "It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth."

Abbott Laboratories expects second quarter 2025 adjusted EPS of $1.23-$1.27 versus consensus of $1.25.

Abbott Laboratories shares gained 0.9% to trade at $130.81 on Thursday.

These analysts made changes to their price targets on Abbott Laboratories following earnings announcement.

Jefferies analyst Matthew Taylor maintained Abbott Laboratories with a Hold and raised the price target from $135 to $137.
Stifel analyst Rick Wise maintained the stock with a Buy and raised the price target from $135 to $145.
Barclays analyst Matt Miksic maintained Abbott Laboratories with an Overweight and raised the price target from $158 to $159.

Considering buying ABT stock? Here’s what analysts think:

Read This Next:

Netflix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2528742345"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2528742345\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2528742345?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-17 23:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2528742345","market":"hk","top_or_hot":-1,"title":"These Analysts Boost Their Forecasts On Abbott Laboratories After Better-Than-Expected Earnings","media":"Benzinga","content":"<html><body><p><strong>Abbott Laboratories</strong> (NYSE:ABT) reported better-than-expected first-quarter adjusted EPS results on Wednesday.</p>\n<p>Abbott Laboratories reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the consensus of $10.40 billion. The U.S. MedTech giant reported adjusted EPS of $1.09, beating the consensus of $1.07 and the management guidance of $1.05-$1.09.</p>\n<p>\"Once again, Abbott's diversified business model delivered top-tier sales and EPS growth,\" said Robert Ford, chairman and CEO of Abbott. \"It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth.\"</p>\n<p>Abbott Laboratories expects second quarter 2025 adjusted EPS of $1.23-$1.27 versus consensus of $1.25.</p>\n<p>Abbott Laboratories shares gained 0.9% to trade at $130.81 on Thursday.</p>\n<p>These analysts made changes to their price targets on Abbott Laboratories following earnings announcement.</p>\n<ul>\n<li>Jefferies analyst Matthew Taylor maintained Abbott Laboratories with a Hold and raised the price target from $135 to $137.</li>\n<li>Stifel analyst Rick Wise maintained the stock with a Buy and raised the price target from $135 to $145.</li>\n<li>Barclays analyst Matt Miksic maintained Abbott Laboratories with an Overweight and raised the price target from $158 to $159.</li>\n</ul>\n<p><strong>Considering buying ABT stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"572\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25-1024x572.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25-1024x572.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25.png 1132w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>Netflix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</strong></li>\n</ul></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These Analysts Boost Their Forecasts On Abbott Laboratories After Better-Than-Expected Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese Analysts Boost Their Forecasts On Abbott Laboratories After Better-Than-Expected Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2025-04-17 23:11</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>Abbott Laboratories</strong> (NYSE:ABT) reported better-than-expected first-quarter adjusted EPS results on Wednesday.</p>\n<p>Abbott Laboratories reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the consensus of $10.40 billion. The U.S. MedTech giant reported adjusted EPS of $1.09, beating the consensus of $1.07 and the management guidance of $1.05-$1.09.</p>\n<p>\"Once again, Abbott's diversified business model delivered top-tier sales and EPS growth,\" said Robert Ford, chairman and CEO of Abbott. \"It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth.\"</p>\n<p>Abbott Laboratories expects second quarter 2025 adjusted EPS of $1.23-$1.27 versus consensus of $1.25.</p>\n<p>Abbott Laboratories shares gained 0.9% to trade at $130.81 on Thursday.</p>\n<p>These analysts made changes to their price targets on Abbott Laboratories following earnings announcement.</p>\n<ul>\n<li>Jefferies analyst Matthew Taylor maintained Abbott Laboratories with a Hold and raised the price target from $135 to $137.</li>\n<li>Stifel analyst Rick Wise maintained the stock with a Buy and raised the price target from $135 to $145.</li>\n<li>Barclays analyst Matt Miksic maintained Abbott Laboratories with an Overweight and raised the price target from $158 to $159.</li>\n</ul>\n<p><strong>Considering buying ABT stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"572\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25-1024x572.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25-1024x572.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17111031/image-25.png 1132w\" width=\"1024\"/></figure>\n<p><strong>Read This Next: </strong></p>\n<ul>\n<li><strong>Netflix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</strong></li>\n</ul></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABT","symbol_name":"雅培","start_time":0,"source_url":"https://www.benzinga.com/25/04/44868231/these-analysts-boost-their-forecasts-on-abbott-laboratories-after-better-than-expected-earnings","article_id":"2528742345","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2528742345","pubTimestamp":1744902672,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":" ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ABT":"雅培"},"translate_title":"这些分析师在盈利好于预期后上调了对雅培实验室的预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABT":1},"content_text":"Abbott Laboratories (NYSE:ABT) reported better-than-expected first-quarter adjusted EPS results on Wednesday.\nAbbott Laboratories reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the consensus of $10.40 billion. The U.S. MedTech giant reported adjusted EPS of $1.09, beating the consensus of $1.07 and the management guidance of $1.05-$1.09.\n\"Once again, Abbott's diversified business model delivered top-tier sales and EPS growth,\" said Robert Ford, chairman and CEO of Abbott. \"It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth.\"\nAbbott Laboratories expects second quarter 2025 adjusted EPS of $1.23-$1.27 versus consensus of $1.25.\nAbbott Laboratories shares gained 0.9% to trade at $130.81 on Thursday.\nThese analysts made changes to their price targets on Abbott Laboratories following earnings announcement.\n\nJefferies analyst Matthew Taylor maintained Abbott Laboratories with a Hold and raised the price target from $135 to $137.\nStifel analyst Rick Wise maintained the stock with a Buy and raised the price target from $135 to $145.\nBarclays analyst Matt Miksic maintained Abbott Laboratories with an Overweight and raised the price target from $158 to $159.\n\nConsidering buying ABT stock? Here’s what analysts think: \n\nRead This Next: \n\nNetflix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}